Pulmonary arterial hypertension (PAH) is a rare but deadly cardiopulmonary disease, which has an unclear and multifactorial pathobiology [1]. Unfortunately, despite availability of 13 Food and Drug Administration-approved therapeutic interventions, the 5-year survival rate is just 21–64% [2]. An important clinical need exists to better understand the molecular mechanisms that lead to PAH development. In addition, a growing interest exists in the use of personalised medicine approaches for PAH, since such a strategy is meritorious in other proliferative diseases, such as cancer [3, 4]. The paucity of patient-derived pulmonary cells has been a limiting factor in the study of pulmonary hypertension; however, new advances have the potential to increase scientific translatability and identify novel mechanisms driving early disease http://bit.ly/2U1AUEw

中文翻译：

---

肺动脉高压治疗成功的秘诀：从肺动脉导管中分离内皮细胞的进展

肺动脉高压(PAH)是一种罕见但致命的心肺疾病，其病理生物学尚不清楚且涉及多种因素[1]。不幸的是，尽管有 13 种食品和药物管理局批准的治疗干预措施可用，但 5 年生存率仅为 21-64% [2]。一个重要的临床需求是更好地了解导致 PAH 发展的分子机制。此外，人们对使用个性化治疗 PAH 的药物越来越感兴趣，因为这种策略在其他增殖性疾病（如癌症）中也很有价值 [3, 4]。患者来源的肺细胞的缺乏一直是肺动脉高压研究的一个限制因素。然而，新的进展有可能提高科学的可转化性并确定导致早期疾病的新机制 http://bit.ly/2U1AUEw